Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02599870 · ClinicalTrials.gov registry record · NA
Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures
A NA study, sponsored by AltheaDx.
- Terminated
- Registry status
- NA
- Development phase
- 56
- Enrollment target
NCT02599870 is a NA study that was terminated before completion, run by AltheaDx. The registered enrollment target is 56 participants.
The verdict
NCT02599870, a NA study, was terminated before completion, sponsored by AltheaDx.
- TERMINATED
- Registry status
- NA
- Development phase
- 56 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) guided treatment when implemented into the pre-operative process for patients undergoing an elective spinal surgical procedure and requiring post-operative acute pain management, as compared to a group of subjects with the same attributes without the guidance of PGx testing for their post-surgery pain management. This study will also evaluate whether PGx testing can reduce narcotic consumption, opioid-related adverse effects, time to mobilization, medical visits and costs.
Interventions
- GENETIC NeuroIDgenetix Test Panel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-02 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02599870
The ClinicalTrials.gov registry entry for NCT02599870 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 56 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AltheaDx, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which NeuroIDgenetix Test Panel is the first listed.
NCT02599870 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02599870 about?
NCT02599870 is a clinical study titled "Clinical Study to Evaluate Clinical Impact of PGx-Guided Treatment for Patients Undergoing Elective Spinal Surgical Procedures". The purpose of this study is to evaluate the effect of pharmacogenetic (PGx) guided treatment when implemented into the pre-operative process for patients undergoing an elective spinal surgical procedure and requiring post-operative acute pain management, as compared to a group of subjects with the ...
What is the current status of trial NCT02599870?
This trial is currently terminated. It is a NA study. The enrollment target is 56 participants. The study started on 2015-09. Estimated completion is 2016-02.
What interventions are being tested in trial NCT02599870?
The interventions under investigation include: NeuroIDgenetix Test Panel (GENETIC).
Who is sponsoring clinical trial NCT02599870?
This trial is sponsored by AltheaDx, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.